Baluretgene parvec

哌巴鲁锐基

Report date: 2025/11/10 15:47:09

Base Information

Drug NameBaluretgene parvec
Drug Alias NameOCU-400AAV-NR2E3AAV-NR-2-E-3AAV5-hNR2E3NR2E3-AAV +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionPhotoreceptor-specific nuclear receptor gene transference
TargetsPhotoreceptor-specific nuclear receptor
Therapy Area/IndicationsKidney DiseasesRetinitis PigmentosaRetinal Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSchepens Eye Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesOcugen IncSchepens Eye Research Institute IncKwang Dong Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsKidney DiseasesRetinitis PigmentosaRetinal Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A